Announcement PDF ASX Announcement 28 Nov 2022 Emyria accepted into National Institutes of Health (NIH) Program HIGHLIGHTS Emyria has been accepted into the NIH HEAL Initiative® National Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP) program. NINDS is part of the U.S. National Institutes of Health (NIH), and the leading funder of neurological research in the USA PSPP will evaluate Emyria’s proprietary formulations of Ultra-Pure cannabinoids for suitability as treatments for pain Emyria to focus its EMD-RX7 cannabinoid program on US-FDA registration pathways Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech, is pleased to announce its acceptance into the Preclinical Screening Platform for Pain Program. Emyria’s Managing Director, Dr. Michael Winlo, said: “We’re delighted to be accepted into this prestigious program to comprehensively evaluate the suitability of our unique, pharmaceutical-grade formulations to address major unmet needs in pain. Our compelling Real World Data [1] has demonstrated that cannabinoids may be useful amongst sufferers of chronic, non-cancer pain and we saw a need to develop reliable, Ultra-Pure dose forms, suitable for registration with major regulators." The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov. The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical models. The PSPP program accepts small molecules, biologics, devices, or natural products for evaluation, from researchers in academia and industry worldwide. Visit : https://heal.nih.gov/research/preclinical-translational/screening-platform - This release has been approved by the Board of Emyria. FOR FURTHER INFORMATION Dr. Michael Winlo Managing Director +61 (0) 8 6559 2800 mwinlo@emyria.com Lexi O’Halloran Investor Relations +61 (0) 404 577 076 investors@emyria.com Emyria ASX Announcement | 28 Nov 2022 Andrew Williams Media Relations +61 (0) 416 583 672 awilliams@emyria.com Sufian Ahmad Corporate Advisor +61 (0) 412 316 162 info@62capital.com.au 1 EMYRIA’S CARE MODEL REDUCING OPIOID USE BY 30% BEFORE CARE AT EMYRIA [2] CARE AT EMYRIA Significant (>30%) reduction in opioid use Average oral morphine equivalent daily dose (oMEDD) trend (Pre vs Post Emyria) for a cohort of high opioid users and >6 months cannabinoid usage Patients with 6+ months of cannabinoid usage Months since first Emyria visit The chart shows the oral morphine equivalent daily dose (“oMEDD”) for a cohort of 220 patients presenting at Emyria’s Emerald Clinics with a “HIGH” opioid consumption rating defined as a daily requirement above 160mg.. oMEDD scores were derived by examining linked community pharmacy dispensing data from NostraData/IQVIA in the 12 months prior and 12 months after starting care at Emerald Clinics. The analysis reveals that these patients had a stable oMEDD scores in the 12 months prior to treatment but experienced a significant average reduction of 30% in their daily oMEDD scores. References: [1] Vickery AW, Roth S, Ernenwein T, Kennedy J, Washer P (2022) A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. PLOS ONE 17(11): e0272241. https://doi.org/10.1371/journal.pone.0272241 [2] See ASX release 07 Jun 2021 Emyria ASX Announcement | 28 Nov 2022 1 UPCOMING DRUG DEVELOPMENT MILESTONES DRUG DEVELOPMENT NEW DRUG DISCOVERY CLINICAL PROGRAMS Ultra-Pure cannabinoid delivery platform PRE-CLINICAL PROGRAM MDMA-like analogues EMD-RX5 “direct-to-consumer” EMD-RX7 “prescription medicine” MDMA-like drug development Formulation optimisation Formulation optimisation Continuous creation & screening Phase 1 study Phase 1 First patent family filed Ethics approved for Phase 3 Pre-IND (FDA) US-focused preclinical program Phase 3 commencement Pivotal trials Metabolic studies Regulatory submission Preclinical assays (multiple animal models) Commercial strategy Australia Human cell line assays Commercial strategy Europe Commercial strategy USA Advanced assay development Lead selection Phase 1 trials ABOUT EMYRIA | emyria.com Global commercial strategy Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via: ● Drug Development: Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria’s first dose form, EMD-RX5 is in Phase 3 trials ● New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest libraries of MDMA-like compounds with partner, the University of Western Australia. ● Proprietary Real-World Data (RWD): Emyria gathers ethically-sourced data with patients cared for at Emyria’s own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Emyria ASX Announcement | 28 Nov 2022 1